Business
Vector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery
(TSXV: PAIN) — Vector Science & Therapeutics (the "Company") today announced the filing of a provisional patent application covering a novel catheter-based platform designed for intratumoral drug delivery research, with an initial scientific focus on pancreatic cancer. The filing initiates a preclinical research program exploring the integration of three delivery and activation modalities in a disease where the scientific rationale for localized, targeted intervention is well established and the
About this update from Vector Science And Therapeutics Corp.
[{"type":"text","content":"Platform Integrates Three Research Modalities Targeting the Electrical Properties of Tumor Biology in Pancreatic Cancer","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"MEQUON, Wis., May 1, 2026 /PRNewswire/ -- (TSXV: PAIN) — Vector Science & Therapeutics (the "Company") today announced the filing of a provisional patent application covering a novel catheter-based platform designed for intratumoral drug delivery research, with an initial scientific focus on pancreatic cancer. The filing initiates a preclinical research program exploring the integration of three delivery and activation modalities in a disease where the scientific rationale for localized, targeted intervention is well established and the unmet need remains significant.","length":588,"tagName":"p"},{"type":"image","alt":"https://vectorscience.co/ (PRNewsfoto/Vector Sciences & Therapeutics)","displaySize":"","headline":null,"caption":"https://vectorscience.co/ (PRNewsfoto/Vector Sciences & Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":91,"url":"https://media.zenfs.com/en/cnwgroup.com/a7dc09657e0a8be805269afdf53523e1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z_TJ3MNukrNvjNinBZDeTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2MA--/https://media.zenfs.com/en/cnwgroup.com/a7dc09657e0a8be805269afdf53523e1","width":400,"height":91}},"href":"https://mma.prnewswire.com/media/2786474/Vector_Sciences_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Pancreatic cancer represents one of oncology's most studied and persistent unmet needs. Approximately 80% of patients are diagnosed at a locally advanced or metastatic stage (National Cancer Institute/NCI), where surgery is not feasible. Despite available systemic regimens, five-year survival rates remain below 5% for this population (NCI), and the literature reflects sustained scientific interest in localized delivery strategies as a complement to or alternative to systemic approaches. Vector's provisional patent describes a platform architecture intended to advance that area of research.","length":604,"tagName":"p"},{"type":"text","content":"The platform integrates three research modalities: intratumoral delivery of cell differentiation agents, electrical ablation based on the differential ...